Gene variants identified by whole-exome sequencing in 33 French women with premature ovarian insufficiency
To investigate the potential genetic etiology of premature ovarian insufficiency (POI).
Whole-exome sequencing (WES) was done on DNA samples from women diagnosed with POI. Mutations identified were analyzed by in silico tools and were annotated according to the guidelines of the American College of Medical Genetics and Genomics. Plausible variants were confirmed by Sanger sequencing.
Four of the 33 individuals (12%) carried pathogenic or likely pathogenic variants, and 6 individuals carried variants of unknown significance. The genes identified with pathogenic or likely pathogenic variants included PMM2, MCM9, and PSMC3IP.
WES is an efficient tool for identifying gene variants in POI women; however, interpretation of variants is hampered by few exome studies involving ovarian disorders and the need for trio sequencing to determine inheritance and to detect de novo variants.
KeywordsPremature ovarian insufficiency Whole-exome sequencing Gene variants
We thank the affected individuals for their participation in this research study on the genetics of premature ovarian insufficiency. We thank the Magee Clinical Genomic Laboratory at Magee-Womens Hospital, UPMC (Pittsburgh, PA), for the whole-exome sequencing.
This research was funded by the National Institute of Child Health and Human Development (R01HD070647 and R21HD074278, A.R.).
Compliance with ethical standards
The study was approved by the Institutional Review Board of University of Pittsburgh (PRO09080427). Informed consent was obtained from all individual participants in the study.
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women. Obstet Gynecol. 2014;124(1):193–7.Google Scholar
- 10.Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.CrossRefGoogle Scholar
- 15.Schiff M, Roda C, Monin M-L, Arion A, Barth M, Bednarek N, et al. Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature. J Med Genet. 2017;54(12):843–51.CrossRefGoogle Scholar
- 16.Sparks SE, Krasnewich DM. PMM2-CDG (CDG-Ia). In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, et al., editors. GeneReviews(®). Seattle (WA): University of Washington, Seattle; 1993.Google Scholar
- 17.Schollen E, Pardon E, Heykants L, Renard J, Doggett NA, Callen DF, et al. Comparative analysis of the phosphomannomutase genes PMM1, PMM2 and PMM2psi: the sequence variation in the processed pseudogene is a reflection of the mutations found in the functional gene. Hum Mol Genet. 1998;7(2):157–64.CrossRefGoogle Scholar
- 25.Desai S, Wood-Trageser M, Matic J, Chipkin J, Jiang H, Bachelot A, et al. MCM8 and MCM9 nucleotide variants in women with primary ovarian insufficiency. J Clin Endocrinol Metab. 2017;102(2):576–82.Google Scholar
- 40.OMIM - Online Mendelian Inheritance in Man [Internet]. cited 2018 Feb 12. Available from: https://omim.org/